These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29295569)

  • 1. Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center.
    Haj A; Doenitz C; Schebesch KM; Ehrensberger D; Hau P; Putnik K; Riemenschneider MJ; Wendl C; Gerken M; Pukrop T; Brawanski A; Proescholdt MA
    Brain Sci; 2017 Dec; 8(1):. PubMed ID: 29295569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
    Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O
    Sharma M; Bellamkonda S; Mohapatra S; Meola A; Jia X; Mohammadi A; Angelov L; Barnett GH; Vogelbaum M; Ahluwalia MS
    World Neurosurg; 2018 Aug; 116():e147-e161. PubMed ID: 29709748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
    Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
    J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
    Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
    Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study.
    Chen J; Wang T; Liu W; Qiu H; Zhang N; Chen X; Ding X; Zhang L
    Front Oncol; 2022; 12():1000501. PubMed ID: 36483042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation.
    Marchi F; Sahnane N; Cerutti R; Cipriani D; Barizzi J; Stefanini FM; Epistolio S; Cerati M; Balbi S; Mazzucchelli L; Sessa F; Pesce GA; Reinert M; Frattini M
    Front Oncol; 2019; 9():1569. PubMed ID: 32039032
    [No Abstract]   [Full Text] [Related]  

  • 10. Survival impact of delaying postoperative chemoradiotherapy in newly-diagnosed glioblastoma patients.
    Zhang M; Xu F; Ni W; Qi W; Cao W; Xu C; Chen J; Gao Y
    Transl Cancer Res; 2020 Sep; 9(9):5450-5458. PubMed ID: 35117910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy.
    Kreth FW; Thon N; Simon M; Westphal M; Schackert G; Nikkhah G; Hentschel B; Reifenberger G; Pietsch T; Weller M; Tonn JC;
    Ann Oncol; 2013 Dec; 24(12):3117-23. PubMed ID: 24130262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.
    Fujii Y; Muragaki Y; Maruyama T; Nitta M; Saito T; Ikuta S; Iseki H; Hongo K; Kawamata T
    J Neurosurg; 2018 Jul; 129(1):1-9. PubMed ID: 28885120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
    Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
    J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of combined intraoperative electrophysiological investigation with 3-T intraoperative MRI for awake cerebral glioma surgery: comprehensive review of the clinical implications and radiological outcomes.
    Ghinda D; Zhang N; Lu J; Yao CJ; Yuan S; Wu JS
    Neurosurg Focus; 2016 Mar; 40(3):E14. PubMed ID: 26926054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T2 Fluid-Attenuated Inversion Recovery Resection for Glioblastoma Involving Eloquent Brain Areas Facilitated Through Awake Craniotomy and Clinical Outcome.
    Lu M; Fu ZH; He XJ; Lu JK; Deng XQ; Lin DL; Gu YM; Fan YF; Lai MY; Li J; Yang MM; Chen ZP
    World Neurosurg; 2020 Mar; 135():e738-e747. PubMed ID: 31899397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series.
    Navarria P; Pessina F; Clerici E; Rossini Z; Franceschini D; D'Agostino G; Franzese C; Comito T; Loi M; Simonelli M; Lorenzi E; Persico P; Politi LS; Grimaldi M; Bello L; Santoro A; Fornari M; Servadei F; Scorsetti M
    J Neurosurg; 2021 Jul; 135(1):64-77. PubMed ID: 32886916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?
    Li YM; Suki D; Hess K; Sawaya R
    J Neurosurg; 2016 Apr; 124(4):977-88. PubMed ID: 26495941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
    Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
    J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.